PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

August 15, 2020

Primary Completion Date

December 13, 2020

Study Completion Date

December 13, 2020

Conditions
COVID-19
Interventions
DRUG

Povidone-Iodine 2%

Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day

DRUG

Povidone-Iodine 0.5%

Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day

DRUG

Isotonic saline 0.9%

Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day

Trial Locations (1)

94305

Stanford Health Care, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04347954 - PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19) | Biotech Hunter | Biotech Hunter